Navigation Links
Serina Therapeutics, Inc. Closes $9.5 Million Financing Round
Date:6/1/2011

HUNTSVILLE, Ala., June 1, 2011 /PRNewswire/ -- Serina Therapeutics, Inc. President and CEO Randall Moreadith, MD, PhD, reported today that Serina has closed on a $9.5 million financing round to advance its lead oncology candidate SER-203 into a Phase I study in humans in early 2012.

"We are pleased to report to our existing and new shareholders the closing of the financing round that was launched in late 2010. This is a very significant milestone for Serina Therapeutics, and will allow us to advance our lead oncology candidate into Phase Ia and continue to build a robust pipeline of novel polymer therapeutics for unmet medical needs," stated Dr. Moreadith.

"Serina's polymer technology has enormous potential to advance novel polymer drugs, not just for oncology but for many diseases including metabolic disorders, pain and inflammation. This capital gives us sufficient resources to advance our first molecule into the clinic, and we wish to express our sincere appreciation to our shareholders."

Serina Therapeutics, Inc. is a private pharmaceutical company located at the HudsonAlpha Institute for Biotechnology in Huntsville, Ala., and is the only company in the world to develop polyoxazoline (POZ) polymers for pharmaceutical applications. POZ polymers are multifunctional polymers that can be coupled to known drugs, and in doing so these novel therapeutics have dramatically altered pharmacokinetics. Molecules that normally have short duration times in the body can be converted to molecules with prolonged activity – sometimes as long as weeks. This prolonged half-life in the body may improve the safety and efficacy of the molecule. In addition, Serina has developed technology that allows the resulting polymer drug to be specifically targeted to receptors on the surface of cancer cells, and this approach may be useful for applications outside oncology. For more information please visit www.serinatherapeutics.com.

Media contact : Holly Ralston (256) 508-8954


'/>"/>
SOURCE Serina Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Serina Therapeutics Awarded Patent for Its Core Polymer Drug Delivery Technology
2. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
3. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
5. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
6. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
7. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
8. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
9. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
10. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
11. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2, 2016  The Addiction Treatment Advisory Group ... Managed Care Pharmacy (AMCP), has released detailed findings ... the opioid addiction crisis, including through improved access ... ATAG,s newly released paper, "The Role of ... addresses many issues around gaps and barriers to ...
(Date:12/2/2016)... 2, 2016 Boston Scientific Corporation (NYSE: ... acquire certain manufacturing assets and capabilities of the Neovasc, ... biological tissue business, as well as a 15% equity ... in cash. The Neovasc advanced biological tissue business makes ... Scientific Lotus™ Valve System. * Upon completion of ...
(Date:12/2/2016)... On Thursday, the NASDAQ Composite ended ... Industrial Average edged 0.36% higher, to finish at 19,191.93; and ... broad based as six out of nine sectors ended the ... the following Services equities: Myriad Genetics Inc. (NASDAQ: ... Research Holdings Inc. (NASDAQ: INCR ), and La ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique wearable technology that measures ... on the market can deliver all that rejiva can. , “Rejiva promotes relaxation and ... than the usual heart rate and steps taken”, adds Evens Augustin, CEO of Rijuven. ...
(Date:12/2/2016)... ... December 02, 2016 , ... "Pro3rd Accents Volume 2 is a ... versatile lower third titles with just a few clicks of the mouse," said Christina ... 30 lower third animations. Choose from various styles with accented animations, rigid boxes, simplistic ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... needy individuals and families from eight different sites throughout Miami-Dade and Broward counties. ... 1,000 volunteers worked very hard on Thanksgiving morning by putting together individual meals ...
(Date:12/2/2016)... ... December 02, 2016 , ... Date aired: ... of Type 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein , Sharon ... of Water, Global Climate Change and Your Health radio program syndicated on Voice ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... that we have been designated as a Cigna Infertility Center of Excellence. The ... performance standards. , “It’s an honor to be designated a Cigna Infertility ...
Breaking Medicine News(10 mins):